The Science of Longevity

A visual map of the strongest current strategies for extending healthspan, from ordinary physiology to experimental geroscience.

LifestylePharmacologyBiotechnology

Healthspan before lifespan

The practical goal of longevity medicine is not simply to add years, but to delay frailty, cardiovascular disease, cancer, neurodegeneration and loss of independence.

Human lifespan is influenced by genetics, early-life conditions, environment, socioeconomic factors, medical care and behavior. No currently available intervention has been proven to dramatically extend maximum human lifespan. The strongest evidence concerns reducing premature mortality and compressing morbidity through conventional risk-factor control.

What drives biological aging?

The modern hallmarks framework describes interconnected processes such as genomic instability, telomere attrition, epigenetic alteration, loss of proteostasis, dysregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem-cell exhaustion, altered intercellular communication, disabled autophagy and chronic inflammation.

Key point

These hallmarks are not percentages of aging. They interact in causal loops, so a therapy that changes one pathway may influence several others.

Major domains of aging biology

Geroscience drugs

Several drugs extend lifespan in model organisms. Human evidence is much less mature, so separating animal efficacy from clinical validation is essential.

Rapamycin / rapalogs

mTOR inhibition reproducibly extends lifespan in mice. Human trials mainly examine immune function, safety and age-related endpoints rather than lifespan.

Metformin

A well-established diabetes drug with extensive observational data. Whether it slows aging in metabolically healthy humans remains unproven.

Senolytics

Compounds such as dasatinib plus quercetin can clear senescent cells in preclinical models. Human studies are early and disease-specific.

Acarbose

Extends lifespan in genetically heterogeneous mice, especially males. In humans it is an established glucose-lowering drug, not an approved longevity therapy.

Evidence maturity

Expected value for healthy aging

The high-value foundation

The least glamorous interventions currently have the strongest human evidence.

  • Exercise: aerobic fitness plus resistance training improves mortality risk, muscle, glucose control, bone and cognition.
  • Blood pressure and lipids: controlling hypertension and atherogenic lipoproteins prevents major causes of late-life disability and death.
  • Diet quality: Mediterranean-style and other minimally processed plant-rich patterns have strong cardiometabolic evidence.
  • Sleep and circadian health: adequate sleep supports metabolic, cardiovascular and cognitive function.
  • Smoking avoidance: one of the largest modifiable effects on lifespan.
  • Vaccination and screening: prevention remains an underappreciated longevity technology.

Experimental frontiers

The most radical approaches aim to repair or reprogram cellular systems rather than treat one disease at a time.

Partial epigenetic reprogramming

Transient expression of reprogramming factors can reverse some age-associated molecular features in cells and animals. Controlling identity loss and tumor risk is a central challenge.

Stage: preclinical

Gene and cell therapies

Gene editing, engineered immune cells and regenerative-cell strategies could eventually target specific causes of age-related disease, but broad rejuvenation remains experimental.

Stage: indication-specific

Plasma and systemic factors

Parabiosis experiments revealed that circulating factors can influence tissue aging in mice. Plasma dilution and factor-targeting approaches are being explored, but human longevity effects are unknown.

Stage: early experimental

A rational hierarchy

Tier 1 — Proven risk reduction: exercise, smoking avoidance, blood-pressure control, lipid management, vaccination, appropriate screening, healthy body composition and adequate sleep.
Tier 2 — Context-dependent interventions: weight-loss drugs, diabetes therapies, targeted supplements and disease-specific prevention when clinically indicated.
Tier 3 — Geroscience experiments: rapalogs, senolytics, NAD precursors, hyperbaric protocols and other approaches with incomplete human outcome data.
Tier 4 — Frontier biotechnology: reprogramming, gene therapy and systemic rejuvenation strategies whose benefit-risk profile is still being defined.